Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Nextech Invest

Founders Alfred Scheidegger

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 81
Average round size
info
The average size of a deal this fund participated in
$89M
Portfolio companies 54
Rounds per year 3.12
Lead investments 16
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 28
Key employees 4
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

Nextech Invest appeared to be the VC, which was created in 1998. The fund was located in Europe if to be more exact in Switzerland. The main department of described VC is located in the Zu00fcrich.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Nextech Invest, startups are often financed by Third Rock Ventures, OrbiMed, 5AM Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Casdin Capital, The Column Group. In the next rounds fund is usually obtained by Future Capital, Wellington Management, The Column Group.

Besides them, we counted 4 critical employees of this fund in our database.

The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Vividion Therapeutics, TetraLogic Pharmaceuticals, Kura Oncology Among the most successful fund investment fields, there are Clinical Trials, Medical Device. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

Comparing to the other companies, this Nextech Invest performs on 35 percentage points more the average number of lead investments. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The higher amount of exits for fund were in 2015. Speaking about the real fund results, this VC is 8 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2019.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Nextech Invest:
Typical Co-investors
Nextech Invest is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Nextech Invest:

Funds with similar focus

Funds from Switzerland
Funds with similar focus located in Switzerland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ProfoundBio

Biotechnology
Therapeutics
$112M13 Feb 2024 Suzhou, Jiangsu, China

Synnovation Therapeutics

Health Care
Life Science
Medical
$102M14 Dec 2023 Wilmington, Delaware, United States

Mariana Oncology

Bioinformatics
Biometrics
Biopharma
Biotechnology
$175M07 Sep 2023 -

K36 Therapeutics

Biotechnology
Therapeutics
$70M28 Jun 2023 Cambridge, Massachusetts, United States

Boundless Bio

Biotechnology
Health Care
Life Science
Therapeutics
$100M16 May 2023 San Diego, California, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$123M22 Mar 2023 Cambridge, Massachusetts, United States

CARGO Therapeutics

Biotechnology
Medical
Therapeutics
$200M01 Mar 2023 Palo Alto, California, United States

Alpha9 Theranostics

Biotechnology
Medical
Product Research
$75M14 Dec 2022 Vancouver, British Columbia, Canada

Alterome Therapeutics

Biopharma
Pharmaceutical
$35M02 Nov 2022 San Diego, California, United States
News
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes

– Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.
Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.
– Hexagon’s interdisciplinary platform combines technological advances and proprietary insights across machine learning, genomics, synthetic biology and automation to systematically discover new chemical compounds linked to known protein targets.
– Hexagon has built a database of microbial genomes that is more than twice the size of all public databases and is adding thousands of additional genomes per month.

Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer

– Atavistik Bio, a pre-clinical biotechnology company pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms, announced that the closing of a $60 million Series A financing round.
– The financing was led by The Column Group and joined by Lux Capital, and Nextech Invest.
– The new financing will support development of Atavistik’s drug discovery platform, and future identification of select drug candidates based on deep knowledge of disease relevant pathways that have evolved over millions of years by nature to be allosterically regulated by metabolites.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Nextech Invest?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 81
Average round size 89M
Rounds per year 3.12
Peak activity year 2021
Lead investments 16
Follow on index 0.33
Exits 28
Group Appearance index 0.96

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

ProfoundBio

Biotechnology
Therapeutics
$112M13 Feb 2024 Suzhou, Jiangsu, China

Synnovation Therapeutics

Health Care
Life Science
Medical
$102M14 Dec 2023 Wilmington, Delaware, United States

Mariana Oncology

Bioinformatics
Biometrics
Biopharma
Biotechnology
$175M07 Sep 2023 -

K36 Therapeutics

Biotechnology
Therapeutics
$70M28 Jun 2023 Cambridge, Massachusetts, United States

Boundless Bio

Biotechnology
Health Care
Life Science
Therapeutics
$100M16 May 2023 San Diego, California, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$123M22 Mar 2023 Cambridge, Massachusetts, United States

CARGO Therapeutics

Biotechnology
Medical
Therapeutics
$200M01 Mar 2023 Palo Alto, California, United States

Alpha9 Theranostics

Biotechnology
Medical
Product Research
$75M14 Dec 2022 Vancouver, British Columbia, Canada

Alterome Therapeutics

Biopharma
Pharmaceutical
$35M02 Nov 2022 San Diego, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: